About the company
PaxMedica Inc, a clinical-stage biopharmaceutical company, is dedicated to advancing the development of innovative anti-purinergic drug therapies (APT) to address a wide range of neurologic disorders with intractable symptoms. With a diverse focus on conditions such as autism spectrum disorder (ASD), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and other related disorders, PaxMedica aims to provide much-needed relief to patients facing these debilitating conditions. One of the flagship product candidates being developed by PaxMedica is PAX-101, an intravenous formulation of suramin. Suramin, originally developed for the treatment of sleeping sickness (East African HAT), has shown promise in treating various neurologic disorders. PaxMedica believes that PAX-101 has the potential to revolutionize the treatment landscape for several indications, including ASD, ME/CFS, and LCS (a condition characterized by symptoms such as light sensitivity, headache, and cognitive dysfunction). Autism spectrum disorder is a complex neurodevelopmental disorder that affects communication, social interaction, and behavior. Currently, there are limited treatment options available for ASD, and the development of targeted therapies is crucial to improve the quality of life for affected individuals. PaxMedica aims to harness the potent anti-purinergic effects of suramin to address the underlying neuroinflammatory processes associated with ASD, potentially offering a breakthrough solution for this challenging condition. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome is another disorder that PaxMedica seeks to tackle with its experimental drug, PAX-101. ME/CFS is a debilitating condition characterized by severe fatigue, post-exertional malaise, cognitive impairment, and other debilitating symptoms. Emerging evidence suggests that viral infections, such as the SARS-CoV-2 virus responsible for COVID-19, may trigger or worsen ME/CFS symptoms in some individuals. With the rising global incidence of ME/CFS due to the long-term effects of COVID-19, there is an urgent need for effective treatment options. PaxMedica sees PAX-101 as a potential therapeutic breakthrough, targeting the purinergic signaling pathway implicated in the pathogenesis of ME/CFS, aiming to alleviate the symptoms and improve the quality of life for affected individuals. In addition to ASD and ME/CFS, PaxMedica is also exploring the potential of PAX-101 for other indications such as LCS, a condition characterized by heightened sensitivity to light leading to severe headaches and cognitive dysfunction. By modulating the purinergic signaling pathway, PAX-101 may be able to provide much-needed relief to individuals suffering from LCS. Through rigorous preclinical and clinical development, PaxMedica is working towards obtaining regulatory approval for PAX-101, ultimately aiming to bring this groundbreaking therapy to patients in need. With its dedication to improving the lives of individuals with neurologic disorders, PaxMedica is at the forefront of innovation, striving to make a lasting impact in the field of anti-purinergic drug therapies.
Website: https://www.paxmedica.com
Data updated: June 2, 2026
